Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.06
+0.13 (1.88%)
May 28, 2026, 1:03 PM EDT - Market open
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Cartesian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.57. The average 1-year stock price forecast is 389.66% higher than the current stock price, while the lowest is $16 (+126.63%) and the highest is $44 (+523.23%).
Price Target: $34.57 (+389.66%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 27, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 27, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $25 | Buy | Maintains | $25 | +254.11% | May 26, 2026 |
| Needham | Needham | Buy Maintains $42 → $40 | Buy | Maintains | $42 → $40 | +466.57% | May 26, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 6, 2026 |
Financial Forecast
Revenue This Year
632.40K
from 2.80M
Decreased by -77.39%
Revenue Next Year
409.53K
from 632.40K
Decreased by -35.24%
EPS This Year
-4.04
from -5.02
EPS Next Year
-3.75
from -4.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.0M | 2.0M | ||||||
| Avg | 632,400 | 409,530 | ||||||
| Low | 98,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -28.7% | 215.5% | ||||||
| Avg | -77.4% | -35.2% | ||||||
| Low | -96.5% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.14 | -2.57 | |||
| Avg | -4.04 | -3.75 | |||
| Low | -4.29 | -4.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.